
<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/joey/Project/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<encodingDesc>
			<appInfo>
				<application version="0.4.2-SNAPSHOT" ident="GROBID" when="2017-08-10T23:34+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Systems biology ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2010">19 2010</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName>
								<forename type="first">Alexander</forename>
								<surname>Lachmann</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pharmacology and Systems Therapeutics</orgName>
								<orgName type="department" key="dep2">Systems Biology Center New York (SBCNY)</orgName>
								<orgName type="department" key="dep3">Mount Sinai School of Medicine</orgName>
								<orgName type="institution">One Gustave Levy Place</orgName>
								<address>
									<postCode>10029</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Huilei</forename>
								<surname>Xu</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pharmacology and Systems Therapeutics</orgName>
								<orgName type="department" key="dep2">Systems Biology Center New York (SBCNY)</orgName>
								<orgName type="department" key="dep3">Mount Sinai School of Medicine</orgName>
								<orgName type="institution">One Gustave Levy Place</orgName>
								<address>
									<postCode>10029</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Jayanth</forename>
								<surname>Krishnan</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pharmacology and Systems Therapeutics</orgName>
								<orgName type="department" key="dep2">Systems Biology Center New York (SBCNY)</orgName>
								<orgName type="department" key="dep3">Mount Sinai School of Medicine</orgName>
								<orgName type="institution">One Gustave Levy Place</orgName>
								<address>
									<postCode>10029</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Seth</forename>
								<forename type="middle">I</forename>
								<surname>Berger</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pharmacology and Systems Therapeutics</orgName>
								<orgName type="department" key="dep2">Systems Biology Center New York (SBCNY)</orgName>
								<orgName type="department" key="dep3">Mount Sinai School of Medicine</orgName>
								<orgName type="institution">One Gustave Levy Place</orgName>
								<address>
									<postCode>10029</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Amin</forename>
								<forename type="middle">R</forename>
								<surname>Mazloom</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pharmacology and Systems Therapeutics</orgName>
								<orgName type="department" key="dep2">Systems Biology Center New York (SBCNY)</orgName>
								<orgName type="department" key="dep3">Mount Sinai School of Medicine</orgName>
								<orgName type="institution">One Gustave Levy Place</orgName>
								<address>
									<postCode>10029</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Avi</forename>
								<surname>Ma &apos;ayan</surname>
							</persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Pharmacology and Systems Therapeutics</orgName>
								<orgName type="department" key="dep2">Systems Biology Center New York (SBCNY)</orgName>
								<orgName type="department" key="dep3">Mount Sinai School of Medicine</orgName>
								<orgName type="institution">One Gustave Levy Place</orgName>
								<address>
									<postCode>10029</postCode>
									<settlement>New York</settlement>
									<region>NY</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName>
								<forename type="first">Olga</forename>
								<surname>Troyanskaya</surname>
							</persName>
							<affiliation key="aff1">
								<orgName type="department">Mahopac High School</orgName>
								<address>
									<addrLine>421 Baldwin Place Road</addrLine>
									<postCode>10541</postCode>
									<settlement>Mahopac</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Systems biology ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments</title>
					</analytic>
					<monogr>
						<title level="j" type="main">BIOINFORMATICS ORIGINAL PAPER</title>
						<imprint>
							<biblScope unit="volume">26</biblScope>
							<biblScope unit="page" from="2438" to="2444"/>
							<date type="published" when="2010">19 2010</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1093/bioinformatics/btq466</idno>
					<note type="submission">Received on February 27, 2010; revised on July 30, 2010; accepted on August 6, 2010</note>
					<note>[14:25 17/9/2010 Bioinformatics-btq466.tex] Page: 2438 2438â€“2444 Associate Editor: Supplementary information: Supplementary data are available at Bioinformatics online.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract>
				<p>Motivation: Experiments such as ChIP-chip, ChIP-seq, ChIP-PET and DamID (the four methods referred herein as ChIP-X) are used to profile the binding of transcription factors to DNA at a genome-wide scale. Such experiments provide hundreds to thousands of potential binding sites for a given transcription factor in proximity to gene coding regions. Results: In order to integrate data from such studies and utilize it for further biological discovery, we collected interactions from such experiments to construct a mammalian ChIP-X database. The database contains 189 933 interactions, manually extracted from 87 publications, describing the binding of 92 transcription factors to 31 932 target genes. We used the database to analyze mRNA expression data where we perform gene-list enrichment analysis using the ChIP-X database as the prior biological knowledge gene-list library. The system is delivered as a web-based interactive application called ChIP Enrichment Analysis (ChEA). With ChEA, users can input lists of mammalian gene symbols for which the program computes over-representation of transcription factor targets from the ChIP-X database. The ChEA database allowed us to reconstruct an initial network of transcription factors connected based on shared overlapping targets and binding site proximity. To demonstrate the utility of ChEA we present three case studies. We show how by combining the Connectivity Map (CMAP) with ChEA, we can rank pairs of compounds to be used to target specific transcription factor activity in cancer cells. Availability: The ChEA software and ChIP-X database is freely available online at: http://amp.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">INTRODUCTION</head><p>Gene expression profiling using microarrays, or now RNA-seq, are popular methods to measure the level of mRNA in mammalian cells at a genome-wide scale. Yet, since mRNA levels only * To whom correspondence should be addressed. weakly correlate with protein level, data collected from mRNA profiling provides little clues on how cells are regulated by the activity of transcription factors, co-regulator complexes and cell signaling pathways. Many methods have been applied to study transcriptional regulation both experimentally and computationally. Recently, large-scale experimental methods that profile the binding of transcription factors to DNA at the genome-wide level have emerged. These methods include ChIP-chip (<ref type="bibr" target="#b5">Iyer et al., 2001</ref>), ChIPseq (<ref type="bibr" target="#b6">Johnson et al., 2007</ref>), ChIP-PET (<ref type="bibr" target="#b26">Wei et al., 2006</ref>) and DamID (<ref type="bibr" target="#b24">Vogel et al., 2007</ref>) (these four methods are referred to as ChIPX for shorthand hereinafter). Results from such experiments report the binding of specific transcription factors to DNA in proximity of target gene loci, commonly listing hundreds to thousands of potential regulatory interactions. Such interactions are often reported in Excel spreadsheets or PDF tables as Supplementary Materials to research articles, or as raw data files provided as short-sequencereads in FASTA format, making such data difficult for reuse. So far, information from genome-wide ChIP-X studies, as well as low-throughput transcription-factor/DNA interaction studies, is utilized to develop binding-site sequence-motifs. For example, JASPAR (<ref type="bibr" target="#b19">Sandelin et al., 2004</ref>) and TRANSFAC (<ref type="bibr" target="#b15">Matys et al., 2003</ref>) are two popular databases that collect information about potential binding sites into logo-motifs also known as binding-site matrices. These databases contain collections of transcription factors with information on regulatory-motif elements. With bindingsite matrices, it is straight forward to map potential binding sites across an entire genome. Alternatively, conserved sequences near gene-coding regions across and within species can suggest transcription-factor binding sites and be used to improve predictions of functional transcription-factor/DNA interactions using multiple alignments combined with logo-motif search. The obvious emerging alternative method is to utilize ChIP-X data for linking transcription factors to gene expression changes by computing binding site overrepresentation. By compiling ChIP-X experiments into a gene-list library database, we can rank transcription factors most likely responsible for the observed changes in gene expression based on statistical enrichment analysis. We show that this method is powerful, capable of capturing interesting underlying biology with clear signals. Such an approach likely works well because it considers the chromatin structure of a specific cellular state, in a specific experiment; and as such, it is a more direct way to infer transcription factor regulation compared to sequence-based methods.Page: 2439 2438â€“2444</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ChEA</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Fig. 1. Screen-shot from</head><p>the ChIP-X database web application. Users can interactively adjust the normalized peak height threshold to determine the genes that are regulated by the transcription factor.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">IMPLEMENTATION</head><p>We manually collected data from ChIP-X experiments into a database of gene lists by extracting lists from the supporting materials of publications. In this ChIP-X database, each record contains a list of genes potentially regulated by a specific transcription factor under a specific condition. We only included publications that describe ChIP-X experiments applied to profile human or mouse cells. Besides manually extracting the gene lists reported by the authors from the publications' supporting materials, when it was possible and available, we also generated gene lists directly from the raw data files that belong to each publication. We implemented our own method for indexing, peak calling and gene matching to process the raw ChIP-seq and ChIP-chip data using a standard process (see Supplementary data for detail). The manually curated portion of the database as of July 26, 2010 contains 189 933 extracted interactions, from 84 publications, describing the binding of 92 transcription factors to 31 932 target genes. Several publications reported target genes for more than one factor, and several factors were profiled by different groups using different conditions and cell types. The automatically generated portion of the database contains 19 ChIP-seq and 10 ChIP-chip publications with 203 ChIP-seq and 22 ChIP-chip individual experiments. Both parts of this ChIP-X database are expected to continually grow. Additionally, since peak height varies significantly across experiments, we also implemented an interactive visualization tool that gives users the control to dynamically set the peak height cut-off for a specific experiment using a slider (<ref type="figure">Fig. 1</ref>). For comparing input gene lists across species, human and mouse gene IDs were merged using homologene. However, species are separated in the database and the user can perform the analysis on each species separately. The automatically generated lists displayed more variability in total gene calling per experiment per transcriptionexperiments for specific transcription factors, including the ability to find which genes are regulated by more than one transcription factor (Supplementary<ref type="figure">Fig. S1</ref>). Users can also browse the content of the database online. The database containing all interactions extracted manually from the ChIP-X experimental data, as well as the indexed files created from the raw data analysis can be downloaded from our web site.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Overlapping target genes among transcription factors</head><p>The collection of gene lists for each transcription factor from the ChIP-X studies allows us to reconstruct initial distance matrices that connect transcription factors based on different measures of binding site similarity. The first approach is based on shared target genes. If two factors share many targets, it is likely that they regulate genes together and potentially physically interact. We used the Jaccard Coefficient and hierarchical clustering to visualize such overlap (<ref type="figure" target="#fig_2">Fig. 3</ref>; Supplementary Figs S2â€“S5). Such analysis unravels known clusters linking the polycomb group members near the selfrenewal embryonic stem-cell members, and clustering cancer related oncogenic transcription factors such as Myc and Cyclin-D1, as well as less obvious relations. Similarity between pairs of transcription factors profiled using ChIP-X studies can be further examined by looking at the proximity of binding peaks. Hence, the second type of distance matrix counts the number of proximal peaks for pairwise factors (Supplementary Figs S6 and S7 and Supplementary Material). Given an arbitrary threshold, such distance matrices can be transformed into networks (Supplementary Figs S8â€“S10). Such networks can be used to further visualize potential transcription factor complexes and help in placing new ChIP-X results within the context of nuclear transcription regulators from prior studies based on target similarity, binding proximity and proteinâ€“protein interactions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Case studies: gene expression analyses with ChEA</head><p>To demonstrate the usefulness of ChEA we used the ChIP-X database for the analysis of mRNA expression data. We demonstrate the utility of the system for three different applications: The first case study is the re-analysis of gene lists that were extracted as biomarker features from two studies that developed a classifier for breast cancer metastasis using tissue from patients profiled with mRNA expression microarrays. The second application is the reanalysis of microarray data collected after over-expression of key transcription factors in embryonic stem cells. Whereas the last example cross references the ChIP-X database with the connectivity map (CMAP), a database of over 6000 chemical perturbations followed by results from genome-wide gene-expression microarrays (<ref type="bibr" target="#b10">Lamb et al., 2006</ref>). Joining the ChIP-X and CMAP databases provides predictions for combinations of small molecule drugs that could be used to potentially down-regulate Myc activity in different cancers.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Case study 1: linking breast cancer signature genes to transcription factors</head><p>The first case study demonstrates how the ChEA system can be used for comparative analysis of two reports that identified a biomarker set for invasive breast cancer inferred from microarray studies. In two independent publications, the authors used two independently collected compendiums of mRNA expression microarrays from patients with breast cancer tumors to find a signature set of genes that can differentiate between benign and malignant breast cancers (van't<ref type="bibr" target="#b23">Veer et al., 2002;</ref><ref type="bibr" target="#b25">Wang et al., 2005</ref>). Both studies produced lists of genes considered as selected feature 'biomarkers'. Surprisingly, the two lists, containing 162 and 73 genes, share very little overlap (two genes) which is statistically insignificant. However, when both gene lists are used as input for ChEA separately, they show enrichment for SMAD2/3 gene targets. The P-value of 2.2E-05 for the list of 73 genes (the third-most significant out of all other experiments in the ChIP-X database) and also 9.5E-05 for the list of the 162 genes (fourth most significant ChIP-X experiment). When the lists are combined, SMAD2/3 is at the top of the list of enriched factors with an improved P-value of 9.3E-10 (<ref type="figure" target="#tab_1">Table 1</ref>; Supplementary Tables S1â€“S4). Careful examination of the 35 genes that were identified as overlapping among the Smad2/3 targets from the two studies point to several genes that have been previously reported to play a role in breast cancer metastasis (Supplementary<ref type="figure">Table S4</ref>). In particular, MMP9 and CD44 are both highly implicated in breast cancer metastasis. MMP9 and CD44 are listed in GeneRifs for 23 and 17 articles returned by the query search 'breast cancer', respectively. MMP9 is a metalo-protease that digests the extra-cellular matrix during invasion, whereas changes in CD44 expression likely play a role in evading the host immune response. The results from the ChEA analysis clearly implicate that TGF-Î²/SMAD2/3 signaling plays a dominant role in breast cancer metastasis and can be used to further explain the origins of the discrepancy between the original Page: 2441 2438â€“2444Complete tables are provided at Supplementary Tables S1â€“S4. two studies. It has been well-established that TGF-Î²/SMAD2/3 signaling is playing an important role in breast cancer metastasis (<ref type="bibr" target="#b8">Koumoundourou D, 2007;</ref><ref type="bibr" target="#b12">Liapis et al., 2007;</ref><ref type="bibr" target="#b28">Xie et al., 2002</ref>). However, the ChEA analysis combined with the microarray profiling provides unbiased global additional support for such hypothesis. Our results also complement a network analysis approach applied to the same data using protein interactions.<ref type="bibr" target="#b3">Chuang et al. (2007)</ref>'connected' the breast cancer biomarkers identified by the two independent studies using known protein-protein interactions to find that a SMAD2/3 sub-network, among other sub-networks, is up-regulated in metastasized tumors. Here we linked such results to transcriptional regulation evidence from ChIP-X studies. Geneexpression profiling from different cancers, collected from patients or cell types, can now be linked to a transcription factor regulatory signature using ChEA. Such signature may hint, in a direct way, to the molecular regulatory mechanisms altered in any specific cancer subtype.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ChEA</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">Case study 2: re-analysis of gene over-expression followed by mRNA profiling of mESCs</head><p>For the second case study, we re-analyzed results from a report where the authors over-expressed 50 transcription factors, one-by-one, in mouse embryonic stem cells (mESCs) and then measured the effect of such perturbations on gene-expression response using mRNA microarrays (<ref type="bibr" target="#b17">Nishiyama et al., 2009</ref>). Among the 50 transcription factors used, all the well-known mESCs regulators are included, i.e. Oct4, Nanog and Sox2. The study identified Cdx2 as the transcription factor with the most dramatic effect when overexpressed, and as such it was selected for conducting a ChIP-seq experiment. We re-analyzed the results from the Nishiyama et al. study by inputting the top 500 genes that changed mostly as compared to the control for each of the 50 perturbations using ChEA. Surprisingly, the two studies that reported ChIP-X results for Suz12 binding appeared as the most statistically enriched for binding sites for almost all of the perturbations (<ref type="figure" target="#fig_3">Fig. 4</ref>; Supplementary<ref type="figure">Table S5</ref>). The P-values for overlap with Suz12 targets were very significant, reaching for example, 1.65E-89 for the up-regulation of Sox9. Additional confidence is added due to the fact that the ChEA database contains two independent Suz12 ChIP-X experiments that do notfully overlap, and both studies appeared at the top for almost all the gain-of-function experiments. Suz12 is a member of the polycomb group (PcG) complex responsible for methylation of lysine 9 and 27 of histone 3. Such methylation is known to cause transcriptional suppression of differentiation genes (<ref type="bibr" target="#b18">Ru and Yi, 2004</ref>). Hence, the fact that all the changes in gene expression observed in this study are strongly associated with Suz12 targets, regardless of the perturbation applied to mESCs, may implicate that almost all perturbations cause differentiation. This suggests that the quantitative level of many components of the self-renewal machinery must be critically balanced to maintain the pluripotency state. It seems that the type of perturbation in itself was less critical as any perturbation induce similar global changes in chromatin rearrangements.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5">Case study 3: cross-referencing ChEA with CMAP for designing multiple drug treatments for cancer</head><p>Another opportunity offered by the ChIP-X database, and the ChEA gene-list enrichment analysis software, is to combine ChEA with the Connectivity Map (CMAP) (<ref type="bibr" target="#b10">Lamb, 2006</ref><ref type="bibr" target="#b11">Lamb, , 2007</ref>). Such combination of databases can be used for identifying and ranking small molecules that can potentially be used for controlling the activity of specific transcription factors. CMAP is a dataset of mRNA microarray expression profiling of drug-stimulated mammalian cancer cells. CMAP contains âˆ¼6000 perturbations with âˆ¼1300 single drugs, sometimes in different concentrations, cell types or other variable experimental conditions. Examining the genes that increased or decreased significantly after a perturbation, we can use ChEA to rank the transcription factors that most likely regulate (statistically over represented transcription factors) the genes that increase or decrease in expression due to the drug perturbation. This ranking can be used to design combinations of drugs that can potentially counteract the activity of specific transcription factors in a specific cellular context (<ref type="figure" target="#fig_4">Fig. 5</ref>). Algorithmically, we can define two families of sets: one describing the relationship between drugs and the mRNAs they affect based on CMAP, and the other family of sets describing transcription factors and their target genes based on entries from the ChIP-X database. The drug-mRNA family of sets DR contains the top 500 genes that increased or decreased in expression given drug i and perturbation Page: 2442 2438â€“2444</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A.Lachmann et al.</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>j</head><p>from CMAP, and where j is used as the set label. Hence, the cardinality of all sets DR j is always 500. Elements in DR j sets are gene symbols. The second family of sets TR is made of target genes from all the ChIP-X experiments. Hence, TR i contains gene symbols reported to be targets of transcription factor i in experiment j where j is the set label. Now we can operate on these families of sets to find the best pair-wise combinations of drugs that cover the target space for transcription factor i. First, we can compute the union of DR with itself to create a new family of sets DP describing how pairs of drugs may affect gene expression in an additive manner. For all DR i and for all DR j where i not equal to j</p><formula>DP k = DR i âˆªDR j</formula><p>The additive assumption was chosen for simplicity, however there is some evidence that it might be reasonable (<ref type="bibr" target="#b4">Geva-Zatorsky et al., 2010</ref>). Hence DP contains a family of (n 2 /2)âˆ’n sets, where n is the number of drug perturbation experiments in CMAP. Note that the family of sets DP contains also genes symbols as the elements of the sets. We are now ready to score how drug perturbation pairs may affect the activity of transcription factor k in experiment j. Such score is simply the intersection between DP and TR,</p><formula>Score = DP i âˆ©TR j</formula><p>The scoring scheme can be used to suggest, for example, how we can use small molecules to induce the activity of specific transcription factors such as Oct4 for iPS reprogramming, or for blocking uncontrolled cell proliferation by targeting Myc. In this case study, we devise mechanisms to down-regulate the activity of the transcription factor Myc and hence potentially block the proliferation of cancer cells. When we examined the results of inputting all lists of the mostly down-regulated 500 genes as reported in the ranked lists from CMAP entered in a batch mode into ChEA, we noticed that Myc appears often as the top-ranked transcription factor for binding in proximity to genes that decreased in expression after many drug perturbations. This is expected since Myc is a known oncogene, and all cell-lines in CMAP are human cancer cells, and many of the drugs that were used to create CMAP are anti-cancer drugs. For illustration, we ranked pairs of drugs based on their combined coverage of Myc targets (<ref type="figure" target="#fig_4">Fig. 5</ref>). Our strategy optimizes selection of drug-pairs that do not have similar effects on Myc targets.<ref type="figure" target="#tab_2">Table 2</ref>provides the resulting top 10 pair-wise entries (a Perl script with an input table is provided as supportingmaterials, Script S1, Supplementary<ref type="figure">Table S6</ref>). The top 10-ranked list of pair-wise drugs suggests combinations of drug treatments for further maximally reducing Myc transcriptional regulatory activity. The combinations we identified include known cancer drugs as well as other drugs. For example, monastrol is a known cancer drug that targets kinesin-5, a motor protein important in mitosis (<ref type="bibr" target="#b16">Mayer et al., 1999</ref>), whereas clonidine is a alpha-adrenergic agonist (<ref type="bibr" target="#b0">AndÃ©n et al., 1970</ref>) that is an anti-hypertensive used to aid sleeping and treat ADHD. Hence, it is likely acting through a different pathway to regulate a subset of Myc-regulated target genes. Our initial approach of combining and ranking pairs of drugs to regulate the activity of specific transcription factors can be further improved in many ways. One possibility is to compute the likelihood that a combination of more than two drugs will cover a specific transcription factor target space. This can be achieved, for example, with algorithms such as the probabilistic generative model for GO enrichment analysis (<ref type="bibr" target="#b13">Lu et al., 2008</ref>). Our initial formulation can also be extended by using quantitative values instead of sets, and include statistical randomization as control. In summary, the approach presented in this third case study provides a step forward toward rationale combinatorial application of drugs to treat specific cancers with a transcription-factor anchoring. Such an approach is amenable also for improving iPS reprogramming strategies by, for example, designing combination of drugs that would activate Oct4 or other key stem-cell self-renewal factors for reprogramming somatic cells into iPS cells. Many other similar applications to attempt to control cell fate are possible. The strategy should also work for other types of gene expression microarray datasets in other contexts.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">DISCUSSION</head><p>One of the reasons high-throughput genome-wide ChIP-X studies are expected to be more useful and accurate than computational sequence-based methods is because the sequence-based approaches do not take into consideration the chromatin state of the cell under a specific experimental condition, cell type or organism. Hence, ChIPX databases and tools such as, cell-types and experimental conditions, using different statistical cut-offs and experimental techniques is challenging. We chose to either use the criteria applied by the authors of each study, or apply our own standard method for finding peaks and calling target genes. Both approaches are simple and relatively unbiased. The two approaches complement each other in regards to coverage. The raw data route excludes many of the studies currently in the database since there are many ChIP-X publications that only provide the target list without the raw data. There are also many ChIP-X raw data files available in the public domain without a publication that contains an author extracted gene list. Regardless, we expect that the database will rapidly continue to grow. Moreover, multiple entries for the same transcription factor can increase the confidence for functional binding sites (<ref type="bibr" target="#b27">Wu and Ji, 2010</ref>). Our initial analysis shows that overlap among different ChIP experiments using the same factor increases functional gene predictability. For example, we examined the overlap among independent Oct4 ChIP-X studies and compared the consensus overlapped genes with an Oct4 knock-down followed by a microarray study. Initial results demonstrate that functional genes prediction improves when multiple independent studies are combined, but this should be further investigated in future studies. Since we keep track in our database on information such as the cell type, organism, experimental method, distance to start site and peak height, we implemented filters that can be used by users to exclude the analysis from including specific organism, cell-type or experimental method; as well as calibrate the gene calling threshold for peak height and distance to start site. For future studies we plan to integrate ChIP-X data with lost-of-function/gain-of-function microarray studies as well as include more histone modification ChIP-X studies. Many of the studies that report global transcription factor binding to DNA using whole genome-wide ChIP-X experiments also often conduct global mRNA experiments after knock-down or over-expression of the transcription factors that were used in the ChIP-X studies, as well as profiling specific histone modifications or polymerase binding using ChIP-X technologies. By combining mRNA microarrays of RNAseq together with ChIP-X transcription factor, polymerase binding and histone modification studies, we can determine which binding sites are functional, as well as which functional sites are activation or inhibition sites. By combining expression data with ChIP-X we should be able to obtain a signed and directed network which is desired for understanding pathways, improving enrichment analyses and performing dynamical simulations. The ChIP-X database and ChEA web-based software tool was generated utilizing code from our previous work of developing a kinase-substrate database and software system for kinase enrichment analysis (KEA) (<ref type="bibr" target="#b9">Lachmann and Ma'ayan, 2009</ref>). These two software systems can potentially be combined. Since we know the group of transcription factors that regulate genes based on changes at the mRNA level under a certain experimental condition or in a specific disease based on tissue expression profiling, we can use known proteinâ€“protein interactions to build a sub-network to connect these transcription factors. Then, we can link this sub-network, as input for KEA, to obtain the protein kinases and pathways that most likely regulate the transcription factor centered sub-network (<ref type="bibr" target="#b2">Bromberg et al., 2008</ref>). Such an approach can be used to understand cell regulation at the cell signaling network level given mRNA expression profiling data and suggest kinase inhibitors as drug-targets (Ma'ayan and He, 2010).</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><figDesc>[14:25 17/9/2010 Bioinformatics-btq466.tex]</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig.2.</head><figDesc>Fig. 2. Screen-shot from the ChEA program web application. Users can cut and paste input lists of genes in the text box on the left. The system reports a ranked list of transcription factors/experiments (concatenated string that includes the transcription factor and the PubMed ID linking the factor to a specific study) based on over-representation of transcription factor putative targets in the input list.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig.3.</head><figDesc>Fig. 3. Transcription factor/target gene similarity distance table based on hierarchical clustering on 122 experiments from the manually extracted ChIP-X database. Transcription factors are considered similar if target genes reported from a ChIP-X study implicate significant overlap (Jaccard's Coefficient). Detailed labels of all experiments are shown in the Supplementary Figures.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig.4.</head><figDesc>Fig. 4. ChEA analysis of the top 500 genes that changed in their mRNA expression after 50 over-expression experiments of single transcription factors in mESCs. The P-value rankings from ChEA for each transcription factor over-expression perturbation are inverse log transformed. The topranked transcription factors reported by ChEA are labeled (peaks in the bar graph). Out of the 50 perturbations, only those factors that reached a low P-value of 1.0E-22 are labeled for clarity. Full results are available in Supplementary Table S5.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig.5.</head><figDesc>Fig. 5. Illustration of the concept of using pair-wise drug perturbations to target the Myc target gene space.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0" validated="true"><figDesc>Table 1. Overlap summary among two prior reports that extracted biomarker sets from microarray mRNA profiling of breast cancer tissue from patients, and the top-ranked ChIP-X study identified by ChEA</figDesc><table>Experiment 
Targets Targets 
P-values 
input (database) 

Van't Veer et al. (2002) E2F1-18555785 
35 
4172 
2.56E-07 
CREB1-15753290 15 
957 
1.15E-06 
CUX1-19635798 
27 
3052 
3.54E-06 
SMAD2/3-18955504 20 
1936 
9.50E-06 

Wang et al. (2005) 
ZFP281-18757296 16 
2004 
7.72E-06 
HNF4A-19822575 29 
6083 
2.20E-05 
SMAD2/3-18955504 15 
1936 
2.23E-05 

Combined 
SMAD2/3-18955504 35 
1936 
9.30E-10 
ZFP281-18757296 32 
2004 
9.58E-08 
E2F1-18555785 
50 
4172 
1.17E-07 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1" validated="true"><figDesc>Table 2. Top-ranked pairs of drug perturbations from CMAP experiments that cover the gene target space of Myc as determined by several ChIP-X experiments independently</figDesc><table>ExpID 

Drug1 
Drug2 
Targets for 
Total 
D1/D2/overlap targets 

monastrol-614 
clonidine-1555 
170/215/8 
377/500 
monastrol-614 
colchicine-1598 
170/210/8 
372/500 
monastrol-614 
tolazoline-2000 
170/208/7 
371/500 
nocodazole-1393 laudanosine-1741 
178/191/6 
363/500 
nocodazole-1393 valproic acid-1047 
178/192/7 
363/500 
monastrol-614 
dihydroergocristine-1745 170/201/8 
363/500 
nocodazole-1393 tolazoline-2000 
178/208/24 
362/500 
monastrol-614 
methylergometrine-1607 
170/203/11 
362/500 
monastrol-614 
bromocriptine-2007 
170/203/11 
362/500 
monastrol-614 
tretinoin-1548 
170/202/10 
362/500 

D1, drug1; D2, drug2; ExpID, experiment ID from CMAP. 

</table></figure>

			<note place="foot">at :: on August 31, 2016 http://bioinformatics.oxfordjournals.org/ Downloaded from</note>

			<note place="foot">factor when using a fixed peak height, in combination with the same indexing and peak calling methods. This suggests that there is intrinsic variability in average peak height and number of identified peaks across different ChIP-seq and ChIP-chip experimensts. The ChIP-X database is utilized to create a web-based interactive software application called ChIP Enrichment Analysis (ChEA) (Fig. 2). With ChEA, users can cut and paste input lists of mammalian gene symbols, typically gene lists that significantly changed in expression level from genome-wide gene expression profiling studies. Then, the software computes over-representation for targets of transcription factors from the ChIP-X database. To compute statistical enrichment, we implemented the Fisher exact test with the Bonferroni&apos;s correction, where the proportions for the test are the number of genes in the input list, the number of genes identified in the ChIP-X experiment, the genes that are shared among the two lists and the number of overall targets in the ChIP-X database (âˆ¼30 000). The program reports a ranked list of ChIP-X experiments that show statistically significant overlap with the input list. Indentified genes from the input list, potentially regulated by a specific transcription factor, are also connected and visualized as a network using known proteinâ€“protein interactions. To construct the proteinâ€“protein interaction network we used the networks we consolidated for the program Genes2Networks (Berger et al., 2007), as well as all mammalian interactions downloaded from the KEGG pathway database (Kanehisa et al., 2008). The ChEA software application and the interactive features of the ChIPX database are implemented with JavaScript, AJAX, Java Server Pages, with a back-end MySQL database, as well as an interactive Adobe Flash-based network and peak-calling viewer developed using ActionScript 3.0. The system can also be downloaded and installed as a standalone Java desktop application, or as a commandline tool. The tool also provides search capabilities for finding transcription factor regulators for specific genes, or for finding</note>

			<note place="foot" n="5"> CONCLUSIONS In summary, the ChIP-X database and the ChEA software provide an alternative way for researchers to analyze mRNA expression data in context of genome-wide transcription-factor ChIP-X experiments collected and organized into a prior knowledge database and an interactive web-based software system. As more transcription factors are profiled, under different experimental conditions, the database is expected to grow and improve in accuracy and coverage. Using other tools and databases in combination with ChEA, integrative creative new applications in systems biology can be made possible. Funding: National Institutes of Health (grants P50GM07155801A27398, R01DK088541, R01GM054508, R01DA15446 and KL2RR029885-0109). Conflict of Interest: none declared.</note>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct   xml:id="b0">
	<analytic>
		<title level="a" type="main">Evidence for a central noradrenaline receptor stimulation by clonidine</title>
		<author>
			<persName>
				<forename type="first">N</forename>
				<forename type="middle">E</forename>
				<surname>AndÃ©n</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Science</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="513" to="523" />
			<date type="published" when="1970" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b1">
	<analytic>
		<title level="a" type="main">Genes2Networks: connecting lists of gene symbols using mammalian protein interactions databases</title>
		<author>
			<persName>
				<forename type="first">S</forename>
				<surname>Berger</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">372</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b2">
	<analytic>
		<title level="a" type="main">Design logic of a cannabinoid receptor signaling network that triggers neurite outgrowth</title>
		<author>
			<persName>
				<forename type="first">K</forename>
				<forename type="middle">D</forename>
				<surname>Bromberg</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="903" to="909" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b3">
	<analytic>
		<title level="a" type="main">Network-based classification of breast cancer metastasis</title>
		<author>
			<persName>
				<forename type="first">H.-Y</forename>
				<surname>Chuang</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Syst. Biol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b4">
	<analytic>
		<title level="a" type="main">Protein dynamics in drug combinations: a linear superposition of individual-drug responses</title>
		<author>
			<persName>
				<forename type="first">N</forename>
				<surname>Geva-Zatorsky</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="643" to="651" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b5">
	<analytic>
		<title level="a" type="main">Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF</title>
		<author>
			<persName>
				<forename type="first">V</forename>
				<forename type="middle">R</forename>
				<surname>Iyer</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">409</biblScope>
			<biblScope unit="page" from="533" to="538" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b6">
	<analytic>
		<title level="a" type="main">Genome-wide mapping of in vivo protein-DNA interactions</title>
		<author>
			<persName>
				<forename type="first">D</forename>
				<forename type="middle">S</forename>
				<surname>Johnson</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">316</biblScope>
			<biblScope unit="page" from="1497" to="1502" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b7">
	<analytic>
		<title level="a" type="main">KEGG for linking genomes to life and the environment</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<surname>Kanehisa</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="480" to="484" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b8">
	<analytic>
		<title level="a" type="main">Prognostic significance of TGFbeta-1 and pSmad2/3 in breast cancer patients with T1-2,N0 tumours</title>
		<author>
			<persName>
				<forename type="first">D</forename>
				<surname>Koumoundourou</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2613" to="2620" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b9">
	<analytic>
		<title level="a" type="main">KEA: kinase enrichment analysis</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Lachmann</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Ma &apos;ayan</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="684" to="686" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b10">
	<analytic>
		<title level="a" type="main">The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Lamb</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="page" from="313" to="1929" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b11">
	<analytic>
		<title level="a" type="main">The connectivity map: a new tool for biomedical research</title>
		<author>
			<persName>
				<forename type="first">J</forename>
				<surname>Lamb</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="54" to="60" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b12">
	<analytic>
		<title level="a" type="main">Effect of the different phosphorylated Smad2 protein localizations on the invasive breast carcinoma phenotype</title>
		<author>
			<persName>
				<forename type="first">G</forename>
				<surname>Liapis</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Apmis</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="104" to="114" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b13">
	<analytic>
		<title level="a" type="main">A probabilistic generative model for GO enrichment analysis</title>
		<author>
			<persName>
				<forename type="first">Y</forename>
				<surname>Lu</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page">109</biblScope>
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b14">
	<analytic>
		<title level="a" type="main">Protein kinase target discovery from genome-wide mRNA expression profiling</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Ma &apos;ayan</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">J</forename>
				<forename type="middle">C</forename>
				<surname>He</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mount Sinai J. Med</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="345" to="349" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b15">
	<analytic>
		<title level="a" type="main">TRANSFAC: transcriptional regulation, from patterns to profiles</title>
		<author>
			<persName>
				<forename type="first">V</forename>
				<surname>Matys</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="374" to="378" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b16">
	<analytic>
		<title level="a" type="main">Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen</title>
		<author>
			<persName>
				<forename type="first">T</forename>
				<forename type="middle">U</forename>
				<surname>Mayer</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">286</biblScope>
			<biblScope unit="page" from="971" to="974" />
			<date type="published" when="1999" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b17">
	<analytic>
		<title level="a" type="main">Uncovering early response of gene regulatory networks in ESCs by systematic induction of transcription factors</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Nishiyama</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Stem. Cell</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="420" to="433" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b18">
	<analytic>
		<title level="a" type="main">SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<surname>Ru</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">Z</forename>
				<surname>Yi</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Cell</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="57" to="67" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b19">
	<analytic>
		<title level="a" type="main">JASPAR: an open-access database for eukaryotic transcription factor binding profiles</title>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Sandelin</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="91" to="94" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b20">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="page" from="25" to="42" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note>btq466. .tex]</note>
</biblStruct>

<biblStruct   xml:id="b21">
	<monogr>
		<title/>
		<author>
			<persName>
				<surname>Page</surname>
			</persName>
		</author>
		<imprint>
			<biblScope unit="page" from="2444" to="2438" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b22">
	<monogr>
		<title/>
		<author>
			<persName>
				<forename type="first">A</forename>
				<surname>Lachmann</surname>
			</persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b23">
	<analytic>
		<title level="a" type="main">Gene expression profiling predicts clinical outcome of breast cancer</title>
		<author>
			<persName>
				<forename type="first">L</forename>
				<forename type="middle">J</forename>
				<surname>Van &apos;t Veer</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">415</biblScope>
			<biblScope unit="page" from="530" to="536" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b24">
	<analytic>
		<title level="a" type="main">Detection of in vivo protein-DNA interactions using DamID in mammalian cells</title>
		<author>
			<persName>
				<forename type="first">M</forename>
				<forename type="middle">J</forename>
				<surname>Vogel</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Protoc</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1467" to="1478" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b25">
	<monogr>
		<title level="m" type="main">Gene-expression profiles to predict distant metastasis of lymphnode-negative primary breast cancer. The Lancet</title>
		<author>
			<persName>
				<forename type="first">Y</forename>
				<surname>Wang</surname>
			</persName>
		</author>
		<imprint>
			<date type="published" when="2005" />
			<biblScope unit="page" from="671" to="679" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b26">
	<analytic>
		<title level="a" type="main">A global map of p53 transcription-factor binding sites in the human genome</title>
		<author>
			<persName>
				<forename type="first">C</forename>
				<forename type="middle">L</forename>
				<surname>Wei</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="207" to="219" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct   xml:id="b27">
	<analytic>
		<title level="a" type="main">JAMIE: joint analysis of multiple ChIP-chip experiments</title>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Wu</surname>
			</persName>
		</author>
		<author>
			<persName>
				<forename type="first">H</forename>
				<surname>Ji</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<date type="published" when="2010" />
		</imprint>
	</monogr>
	<note>[. Epub ahead of print]</note>
</biblStruct>

<biblStruct   xml:id="b28">
	<analytic>
		<title level="a" type="main">Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study</title>
		<author>
			<persName>
				<forename type="first">W</forename>
				<surname>Xie</surname>
			</persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="497" to="505" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>